SRS Sequential Sindilimab in Brain Metastasis of NSLSC
Launched by XIAORONG DONG · Nov 26, 2019
Trial Information
Current as of April 30, 2025
Unknown status
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • non-small cell lung cancer patients with less than brain metastases
- • Patients must have received at least the first-line anti-tumor treatment, and the front-line treatment must include chemotherapy or targeted treatment with a platinum containing combination scheme, but not anti-PD-1 / L1 treatment
- • Patients who have not received intracranial local treatment before
- Exclusion Criteria:
- • Patients who toke major surgery within 4 weeks prior to enrollment or had ununited wounds
- • Patients with hemorrhage in intracranial metastasis
About Xiaorong Dong
Xiaorong Dong is a dedicated clinical trial sponsor committed to advancing medical research and innovation. With a focus on developing novel therapies and treatments, the organization collaborates with leading researchers and institutions to conduct rigorous clinical trials. Xiaorong Dong emphasizes patient safety, ethical standards, and scientific integrity in all its projects, aiming to contribute meaningful solutions to unmet medical needs. Through its comprehensive approach, the sponsor strives to enhance healthcare outcomes and improve the quality of life for patients globally.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Wuhan, Hubei, China
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials